Harbor Capital Advisors Inc. Has $14.15 Million Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Harbor Capital Advisors Inc. boosted its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 56.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 128,913 shares of the medical equipment provider's stock after acquiring an additional 46,262 shares during the quarter. Lantheus accounts for 0.6% of Harbor Capital Advisors Inc.'s portfolio, making the stock its 24th largest position. Harbor Capital Advisors Inc. owned about 0.19% of Lantheus worth $14,148,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Daiwa Securities Group Inc. acquired a new position in shares of Lantheus in the 1st quarter worth approximately $1,269,000. Nordea Investment Management AB lifted its position in Lantheus by 42.6% during the 1st quarter. Nordea Investment Management AB now owns 47,322 shares of the medical equipment provider's stock worth $2,932,000 after buying an additional 14,147 shares in the last quarter. Hancock Whitney Corp grew its holdings in Lantheus by 265.6% during the 1st quarter. Hancock Whitney Corp now owns 20,151 shares of the medical equipment provider's stock worth $1,254,000 after acquiring an additional 14,639 shares during the last quarter. Wealth Enhancement Advisory Services LLC acquired a new position in shares of Lantheus during the second quarter worth approximately $290,000. Finally, Pitcairn Co. grew its stake in shares of Lantheus by 117.0% during the first quarter. Pitcairn Co. now owns 8,364 shares of the medical equipment provider's stock valued at $521,000 after purchasing an additional 4,509 shares during the last quarter. 99.06% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Lantheus news, President Paul Blanchfield sold 2,000 shares of the business's stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of $96.39, for a total transaction of $192,780.00. Following the transaction, the president now owns 98,980 shares of the company's stock, valued at $9,540,682.20. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, Director Gerard Ber sold 15,500 shares of the business's stock in a transaction on Monday, August 12th. The stock was sold at an average price of $96.48, for a total value of $1,495,440.00. Following the completion of the sale, the director now directly owns 21,221 shares in the company, valued at $2,047,402.08. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, President Paul Blanchfield sold 2,000 shares of Lantheus stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $96.39, for a total value of $192,780.00. Following the sale, the president now directly owns 98,980 shares of the company's stock, valued at $9,540,682.20. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 1.50% of the company's stock.

Lantheus Stock Down 1.7 %

NASDAQ:LNTH traded down $1.86 on Friday, hitting $107.98. 576,149 shares of the company's stock were exchanged, compared to its average volume of 509,573. The firm has a 50-day moving average price of $108.13 and a 200-day moving average price of $94.63. Lantheus Holdings, Inc. has a 52 week low of $50.20 and a 52 week high of $126.89. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.68 and a quick ratio of 4.41. The company has a market cap of $7.50 billion, a P/E ratio of 17.70 and a beta of 0.51.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its quarterly earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 EPS for the quarter, missing the consensus estimate of $1.68 by ($0.07). The company had revenue of $394.10 million for the quarter, compared to analyst estimates of $382.12 million. Lantheus had a net margin of 29.80% and a return on equity of 48.36%. The business's revenue for the quarter was up 22.5% on a year-over-year basis. During the same period last year, the company posted $1.40 earnings per share. As a group, analysts expect that Lantheus Holdings, Inc. will post 5.99 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently commented on the company. Leerink Partners lifted their price objective on Lantheus from $106.00 to $127.00 and gave the stock an "outperform" rating in a research report on Thursday, July 11th. Truist Financial reduced their price objective on shares of Lantheus from $141.00 to $135.00 and set a "buy" rating on the stock in a research note on Thursday, August 1st. Redburn Atlantic began coverage on shares of Lantheus in a report on Tuesday, September 3rd. They set a "buy" rating and a $175.00 target price for the company. B. Riley raised their price target on Lantheus from $105.00 to $146.00 and gave the stock a "buy" rating in a research report on Thursday, July 25th. Finally, JMP Securities dropped their price objective on Lantheus from $130.00 to $125.00 and set a "market outperform" rating for the company in a report on Thursday, August 1st. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, Lantheus has an average rating of "Moderate Buy" and a consensus price target of $126.00.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.